Skip to main content

Table 4 Univariate analysis of demographic data, clinicopathological data, and circulating CD45neg subpopulations with PFS and OS, computed from both the diagnosis of metastasis and the CTC assessment

From: In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis

Variable OS (from stage IV diagnosis) OS (from CTC assessment) PFS
  HR 95 % CI p HR 95 % CI p HR 95 % CI p
ECOG PS 2-3 vs. 0-1 5.288 1.392–20.096 0.015 11.294 2.467–51.702 0.0018 2.558 0.730–8.963 0.14
BC profile HER2-positive vs. luminal 0.338 0.075–1.525 0.16 0.274 0.061–1.235 0.092 0.616 0.237–1.599 0.32
  TNBC vs. luminal 1.803 0.564–5.771 0.32 0.972 0.312–3.029 0.96 1.212 0.495–2.963 0.67
Lines received > 2 vs. < 2 3.452 1.138–10.475 0.029 0.622 0.245–1.581 0.32 0.557 0.265–1.172 0.12
Age ≥ 70 vs. < 70 0.593 0.19–1.809 0.34 0.652 0.213–1.997 0.45 1.031 0.459–2.314 0.94
E CTC (n) 1.003 0.982–1.024 0.79 1.001 0.980–1.023 0.92 1.004 0.989–1.020 0.6
EM CTC (n) 1.018 0.994–1.043 0.13 1.023 0.998–1.049 0.08 1.020 0.998–1.043 0.081
ETOT CTC (n) 1.006 0.993–1.019 0.35 1.006 0.993–1.019 0.38 1.007 0.996–1.018 0.24
MES (n) 0.998 0.991–1.005 0.56 0.998 0.991–1.005 0.56 0.998 0.992–1.003 0.41
NEG (n) 0.998 0.981–1.015 0.79 0.992 0.975–1.010 0.41 0.997 0.986–1.008 0.58
CD45neg (n) 0.999 0.994–1.004 0.79 0.999 0.993–1.004 0.61 0.999 0.995–1.003 0.56
EM CTC/CD45neg (%) 1.022 1.003–1.042 0.022 1.035 1.013–1.057 0.0016 1.021 1.004–1.039 0.016
E TOT/CD45neg (%) 1.019 1.004–1.034 0.015 1.019 1.004–1.034 0.013 1.010 0.997–1.023 0.12
MES/CD45neg (%) 0.984 0.968–0.999 0.037 0.988 0.973–1.002 0.1 0.993 0.981–1.005 0.26
NEG/CD45neg (%) 0.999 0.972–1.027 0.95 0.992 0.966–1.018 0.54 0.998 0.980–1.017 0.86
  1. Bold cells indicate significant (p <0.05) association as detected by univariate Cox regression model
  2. CI confidence interval, CTC circulating tumor cells, ECOG PS Eastern Cooperative Oncology Group Performance Status, E CTC subset of CD45neg expressing epithelial markers only, EM CTC subset of CD45neg coexpressing mesenchymal and epithelial markers, ETOT CTC CD45neg cells expressing epithelial markers independently from the expression of mesenchymal markers, HR hazard ratio, MES subset of CD45neg expressing mesenchymal markers only, NEG subset of CD45neg negative to the antibody cocktail, OS overall survival, PFS progression-free survival, BC breast cancer, HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer